These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 8311115

  • 21. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators.
    Patel DD, Bhatavdekar JM, Chikhlikar PR, Ghosh N, Suthar TP, Shah NG, Mehta RH, Balar DB.
    J Surg Oncol; 1996 Jun; 62(2):86-92. PubMed ID: 8649046
    [Abstract] [Full Text] [Related]

  • 22. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.
    Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K.
    Clin Cancer Res; 2003 Feb; 9(2):716-21. PubMed ID: 12576440
    [Abstract] [Full Text] [Related]

  • 23. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D, Juretić A, Sarcević B, Separović V, Kujundzić-Tiljak M, Hudolin T, Spagnoli GC, Cović D, Samija M.
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [Abstract] [Full Text] [Related]

  • 24. Prognostic markers in node-negative breast cancer: a prospective study.
    Kute TE, Russell GB, Zbieranski N, Long R, Johnston S, Williams H, Stackhouse C, Wilkins L, Evans I, Berry P, Rimmer K, Tucker E.
    Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
    [Abstract] [Full Text] [Related]

  • 25. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ, Huh SJ, Yang JH, Park W, Nam SJ, Kim JH, Lee JH, Kang SS, Lee JE, Kang MK, Park YJ, Nam HR.
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [Abstract] [Full Text] [Related]

  • 26. E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survival.
    Guriec N, Marcellin L, Gairard B, Caldéroli H, Wilk A, Renaud R, Bergerat JP, Oberling F.
    Invasion Metastasis; 1996 Mar; 16(1):19-26. PubMed ID: 8830762
    [Abstract] [Full Text] [Related]

  • 27. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.
    Carreño G, Del Casar JM, Corte MD, González LO, Bongera M, Merino AM, Juan G, Obregón R, Martínez E, Vizoso FJ.
    Breast Cancer Res Treat; 2007 Mar; 102(1):61-73. PubMed ID: 16850244
    [Abstract] [Full Text] [Related]

  • 28. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
    Scorilas A, Talieri M, Ardavanis A, Courtis N, Dimitriadis E, Yotis J, Tsiapalis CM, Trangas T.
    Cancer Res; 2000 Oct 01; 60(19):5427-33. PubMed ID: 11034084
    [Abstract] [Full Text] [Related]

  • 29. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients.
    Scorilas A, Diamandis EP, Levesque MA, Papanastasiou-Diamandi A, Khosravi MJ, Giai M, Ponzone R, Roagna R, Sismondi P, López-Otin C.
    Clin Cancer Res; 1999 Jul 01; 5(7):1778-85. PubMed ID: 10430082
    [Abstract] [Full Text] [Related]

  • 30. Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors.
    Pirinen R, Lipponen P, Syrjänen K.
    Anticancer Res; 1995 Jul 01; 15(6B):2835-40. PubMed ID: 8669874
    [Abstract] [Full Text] [Related]

  • 31. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
    Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM.
    Cancer; 2003 Feb 01; 97(3):545-53. PubMed ID: 12548595
    [Abstract] [Full Text] [Related]

  • 32. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H, Levesque MA, Clark GM, Diamandis EP.
    Br J Cancer; 1999 Oct 01; 81(3):490-5. PubMed ID: 10507775
    [Abstract] [Full Text] [Related]

  • 33. Prostate-specific antigen value as a marker in breast cancer.
    Narita D, Cimpean AM, Anghel A, Raica M.
    Neoplasma; 2006 Oct 01; 53(2):161-7. PubMed ID: 16575473
    [Abstract] [Full Text] [Related]

  • 34. An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma.
    MacConmara M, O'Hanlon DM, Kiely MJ, Connolly Y, Jeffers M, Keane FB.
    Int J Oncol; 2002 Apr 01; 20(4):717-21. PubMed ID: 11894115
    [Abstract] [Full Text] [Related]

  • 35. [The value of searching for additional prognostic factors in combination with Nottingham Prognostic Index in breast carcinoma patients].
    Jakić-Razumović J, Corić M, Vrbanec D, Babić D, Hlupić L, Belev B.
    Lijec Vjesn; 2005 Apr 01; 127(1-2):3-7. PubMed ID: 16145866
    [Abstract] [Full Text] [Related]

  • 36. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A, International Breast Cancer Study Group.
    Cancer; 2003 Apr 01; 97(7):1591-600. PubMed ID: 12655514
    [Abstract] [Full Text] [Related]

  • 37. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M.
    Cancer Res; 1993 Jun 01; 53(11):2513-21. PubMed ID: 8388317
    [Abstract] [Full Text] [Related]

  • 38. Prognostic value of c-erbB2 expression in breast cancer.
    Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S.
    J Surg Oncol; 2002 Apr 01; 79(4):216-23. PubMed ID: 11920778
    [Abstract] [Full Text] [Related]

  • 39. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 40. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status.
    Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA.
    Cancer; 2009 Nov 01; 115(21):4917-23. PubMed ID: 19691094
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.